Advanced Search: ALL

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email Patient_Care_Coordination_Center@bjc.org.

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

201108251

Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of Lymphoid Malignancies

201606146

A Phase IIa Study of BL-8040 in Combination with Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

201712157

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39) with Newly Diagnosed Precursor B-Cell ALL

201901148

A phase II study of inotuzumab ozogamicin followed by blinatumomab for Ph-negative, CD22-positive B-lineage acute lymphoblastic leukemia in newly diagnosed older adults or adults with relapsed or refractory disease

201912013

A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients with Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

201901079

Developing biomarkers for chemotherapy-induced peripheral neuropathy

202004253

AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA

202009151

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies